[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hospital-length-of-stay\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hospital-length-of-stay":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100592413","phase-4-pasteurised-donor-human-milk-supplementation-for-term-babies-100592413",false,"NCT06993103","Pasteurised Donor Human Milk Supplementation for Term Babies","A Randomised Controlled Trial of Pasteurised Donor Human Milk as Supplementary Nutrition for Infants Born to Women With Diabetes in Pregnancy.","PRESENT","Inclusion Criteria:\n\nEach participant must meet all the following criteria to be enrolled in this trial:\n\n* Mother is \\>18 years at the time of consent\n* Mother has diabetes in pregnancy (type 1, type 2 or gestational diabetes)\n* Mother intends to breastfeed for at least 6 weeks at the time of consent.\n* Infant is born at ≥ 37 weeks and weighs \\> 2.5kg\n* Clinician caring for infant decides that supplementary nutrition (in addition to maternal breast milk) is required within the first 48 hours after birth.\n* Parent\u002Fs provide\u002Fs a signed and dated informed consent form and has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf.\n\nExclusion Criteria:\n\nMother\u002Finfant pairs meeting any of the following criteria will be excluded from the trial:\n\n* Multiple pregnancy\n* Mother has a condition that precludes maternal breast milk consumption e.g. HIV, receiving chemotherapy\n* Infant has clinically significant congenital abnormality interfering with effective breastfeeding or breast milk consumption (e.g., cleft lip and palate, metabolic disorder) and\u002For requiring immediate care in a neonatal unit (e.g., congenital heart disease).\n* Infant has received infant formula prior to randomisation.\n* Infant admitted to neonatal intensive care prior to randomisation.\n* More than 48 hours old at the time of recruitment","ALL","0 Hours","48 Hours",{"count":21,"type":22},1444,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","PRESENT is a multi-center randomised controlled trial that aims to assess whether access to pasteurized donor human milk as supplementary nutrition in the first five days of life for term infants born to women with diabetes in pregnancy reduces the proportion of infants who are admitted to a neonatal unit for management of hypoglycemia compared with current standard hospital care. The trial will also assess other important outcomes including breastfeeding rates, maternal mental health, and infant cow's milk allergy.\n\nThere will be two treatment arms. In the intervention arm, PDHM will be made available to infants from randomisation until day 5 of life. Infants allocated to the control arm will receive care as per local unit policy, including supplemental nutrition as recommended by the treating clinician. After hospital discharge, participants will be asked to complete an electronic questionnaire at 2 \\& 6 weeks and 6 \\& 12 months after birth. Questionnaires will assess infant feeding practices, maternal quality of life \\[including anxiety and depression symptoms and health-related quality of life\\] along with infant cow's milk allergy symptoms.",[28,29,30,31,32,33,34],"Neonatal Hypoglycemia","Metabolic Complication","Cows Milk Allergy","Hospital Length of Stay","Neonatal Intensive Care Unit","Breastfeeding","Mental Health Issue",[36,37],"Pasteurised donor human milk","Donor breastmilk","RECRUITING","2026-01-29",{"date":41,"type":42},"2026-02-02","ACTUAL",{"date":44,"type":42},"2025-12-04",{"date":46,"type":22},"2028-12",{"name":48,"class":49},"The University of Queensland","OTHER",4,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100590307","use-of-point-of-care-ultrasound-pocus-to-reduce-hospital-length-of-stay-in-patients-with-heart-failure--pocushf--100590307","NCT06965712","Use of Point-of-Care Ultrasound (POCUS) to Reduce Hospital Length of Stay in Patients With Heart Failure ( POCUSHF )","Use of Point-of-Care Ultrasound (POCUS) to Guide Fluid Management and Reduce Hospital Length of Stay in Patients With Decompensated Heart Failure","POCUSHF","Inclusion Criteria:\n\nAdults aged 18 years and older.\n\nHospitalized with a primary diagnosis of decompensated heart failure (left, right, or biventricular).\n\nEvidence of volume overload or congestion based on Framingham criteria, clinical examination, elevated proBNP (\\>1000 pg\u002FmL), or chest X-ray showing pulmonary edema.\n\nAbility to undergo bedside ultrasound evaluation (POCUS) as clinically feasible.\n\nAble to provide informed consent.\n\nExclusion Criteria:\n\nAge under 18 years.\n\nPregnant or breastfeeding women.\n\nTerminal illness with life expectancy \\\u003C 30 days.\n\nInability to obtain ultrasound images due to body habitus or other technical reasons.\n\nEnrollment in another interventional clinical trial that could interfere with the outcomes of this study.","18 Years",{"count":61,"type":22},66,[63],"NA","This study will evaluate whether using bedside ultrasound (also called Point-of-Care Ultrasound or POCUS) can help improve the care of hospitalized patients with decompensated heart failure. Patients will be randomly assigned to two groups: one group will receive ultrasound-guided assessments, and the other group will receive standard clinical evaluations. Researchers will compare the hospital length of stay between the two groups. Ultrasound is a non-invasive, safe, and painless imaging tool. The goal of the study is to find out if ultrasound guidance can lead to shorter hospitalizations and better care for patients with heart failure.",[66,67,31],"Heart Failure","Decompensated Heart Failure",[66,67,69,70,31,71,72,73,74,75],"Point-of-Care Ultrasound","POCUS","Ultrasound-Guided Therapy","Lung Ultrasound","Inferior Vena Cava Ultrasound","Volume Status Assessment","Readmission Prevention","2026-01-13",{"date":78,"type":42},"2026-01-14",{"date":80,"type":42},"2025-11-24",{"date":82,"type":22},"2026-06-30",{"name":84,"class":49},"Florida International University",1]